Zhao, HenanYu, XiaotangDing, YanfangZhao, JinyaoWang, GuangWu, XianJiang, JiyongPeng, ChunGuo, Gordon ZhuoCui, Shiying2017-07-072017-07-072016-08-16Zhao, H., Yu, X., Ding, Y., Zhao, J., Wang, G., Wu, X., … Cui, S. (2016). MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2. Oncotarget, 7(33), 53254–53268. http://doi.org/10.18632/oncotarget.10736https://hdl.handle.net/1805/13337In this study, we examined the role of the miRNA miR-770-5p in cisplatin chemotherapy resistance in ovarian cancer (OVC) patients. miR-770-5p expression was reduced in platinum-resistant patients. Using a 6.128-fold in expression as the cutoff value, miR-770-5p expression served as a prognostic biomarker and predicted the response to cisplatin treatment and survival among OVC patients. Overexpression of miR-770-5p in vitro reduced survival in chemoresistant cell lines after cisplatin treatment. ERCC2, a target gene of miR-770-5p that participates in the NER system, was negatively regulated by miR-770-5p. siRNA-mediated silencing of ERCC2 reversed the inhibition of apoptosis resulting from miR-770-5p downreglation in A2780S cells. A comet assay confirmed that this restoration of cisplatin chemosensitivity was due to the inhibition of DNA repair. These findings suggest that endogenous miR-770-5p may function as an anti-oncogene and promote chemosensitivity in OVC, at least in part by downregulating ERCC2. miR-770-5p may therefore be a useful biomarker for predicting chemosensitivity to cisplatin in OVC patients and improve the selection of effective, more personalized, treatment strategies.en-USAttribution-NonCommercial-NoDerivs 3.0 United StatesOvarian cancerCisplatinChemoresisitancemiR-770-5pERCC2Article